A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration in Patients With Type 1 Diabetes on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study

Trial Profile

A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration in Patients With Type 1 Diabetes on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Empagliflozin (Primary) ; Ramipril
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BETWEEN
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 Apr 2017 Status changed from active, no longer recruiting to recruiting.
    • 24 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Nov 2016 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top